Daxor Corporation (DXR)
Largest Insider Buys in Sector
DXR Stock Price History Chart
DXR Stock Performance
About Daxor Corporation
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 …
Insider Activity of Daxor Corporation
Over the last 12 months, insiders at Daxor Corporation have bought $13,735 and sold $0 worth of Daxor Corporation stock.
On average, over the past 5 years, insiders at Daxor Corporation have bought $39,455 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Michel Robert J (Chief Financial Officer) — $13,050. Feuer Edward (director) — $7,210.
The last purchase of 45,000 shares for transaction amount of $0 was made by Feldschuh Michael Richard (Chief Executive Officer) on 2024‑12‑06.
List of Insider Buy and Sell Transactions, Daxor Corporation
| 2024-12-06 | Chief Executive Officer | 45,000 – | $0 | $0 | -5.51% | |||
| 2024-12-06 | Chief Scientific Officer | 32,000 – | $0 | $0 | -5.51% | |||
| 2024-03-27 | Chief Financial Officer | 750 0.0161% | $8.70 | $6,525 | +5.13% | |||
| 2024-03-04 | director | 1,000 0.0212% | $7.21 | $7,210 | +25.17% | |||
| 2023-12-06 | Chief Financial Officer | 120 0.0025% | $7.75 | $930 | +12.14% | |||
| 2023-12-01 | Chief Executive Officer | 800 0.0166% | $7.80 | $6,240 | +13.63% | |||
| 2023-12-01 | Chief Financial Officer | 180 0.0037% | $7.75 | $1,395 | +13.63% | |||
| 2023-11-24 | Chief Financial Officer | 500 0.0104% | $7.94 | $3,970 | +12.09% | |||
| 2023-11-10 | CHIEF EXECUTIVE OFFICER | 1,001 0.021% | $7.83 | $7,838 | +13.97% | |||
| 2023-11-09 | CHIEF EXECUTIVE OFFICER | 401 0.0082% | $7.85 | $3,148 | +11.54% | |||
| 2023-10-13 | Chief Financial Officer | 500 0.0106% | $9.02 | $4,510 | -0.67% | |||
| 2023-05-24 | CEO & President | 2,000 0.0494% | $9.75 | $19,500 | -1.14% | |||
| 2023-05-24 | director | 300 0.0074% | $9.75 | $2,925 | -1.14% | |||
| 2023-03-27 | Chief Financial Officer | 4,750 – | $0 | $0 | ||||
| 2022-11-18 | Chief Financial Officer | 1,000 0.025% | $10.00 | $10,000 | -3.23% | |||
| 2022-11-17 | director | 3,157 0.0745% | $9.50 | $29,992 | -3.81% | |||
| 2021-04-19 | CHIEF FINANCIAL OFFICER | 1,000 0.0245% | $10.25 | $10,250 | +5.22% | |||
| 2021-04-16 | CEO & President | 4,200 0.1033% | $10.33 | $43,386 | +4.47% | |||
| 2019-03-22 | CHIEF FINANCIAL OFFICER | 750 0.0194% | $13.02 | $9,765 | -24.68% | |||
| 2019-03-21 | CEO & President | 1,200 0.0297% | $12.35 | $14,818 | -23.82% |
Insider Historical Profitability
| Feldschuh Michael Richard | Chief Executive Officer | 207492 4.2897% | $7.95 | 32 | 1 | +6.75% |
| Feldschuh Jonathan Adam | Chief Scientific Officer | 35908 0.7424% | $7.95 | 1 | 1 | |
| Michel Robert J | Chief Financial Officer | 11300 0.2336% | $7.95 | 10 | 0 | +27.82% |
| Feuer Edward | director | 1000 0.0207% | $7.95 | 2 | 0 | +30.13% |
| FELDSCHUH JOSEPH | 10 percent owner | 2774455 57.3598% | $7.95 | 105 | 3 | +24.27% |
Institutional Investor Ownership
| The Vanguard Group | $420,746.00 | 0.98 | 47,328 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $136,000.00 | 0.32 | 15,321 | 0% | +$0 | <0.0001 | |
| UBS | $10,312.00 | 0.02 | 1,160 | New | +$10,312.00 | <0.0001 | |
| Morgan Stanley | $1,556.00 | <0.01 | 175 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $42.00 | <0.01 | 5 | +25% | +$8.40 | <0.0001 |